Cytokinetics reports additional Phase III data for suspended ALS candidate

Cytokinetics Inc. (NASDAQ:CYTK) reported additional data from the Phase III VITALITY-ALS trial in 744 patients with amyotrophic lateral sclerosis (ALS) showing

Read the full 219 word article

User Sign In